Stephen Begbie

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

Pharmacy, Oncology, Pharmacotherapy +17

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Olga Kondrashova, Monique Topp, Ksenija Nesic et al. · Nature Communications · 2018 · 292 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

John C. Araujo, Géralyn C. Trudel, Fred Saad et al. · The Lancet Oncology · 2013 · 231 citations

Medicine, Oncology, Urology +14

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14